Droxidopa for POTS
Droxidopa is NOT recommended for the treatment of POTS, as it is FDA-approved only for neurogenic orthostatic hypotension (nOH), not POTS, and current guidelines do not include it among recommended pharmacological therapies for POTS.
Why Droxidopa Is Not Appropriate for POTS
The 2020 Canadian Cardiovascular Society guidelines explicitly list the most common medications used in POTS management as: midodrine, propranolol, pyridostigmine, fludrocortisone, ivabradine, clonidine, and intermittent IV normal saline 1. Droxidopa is notably absent from this list.
The FDA label for droxidopa clearly states it is indicated for "symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure" 2. POTS is fundamentally different from nOH—POTS is defined by excessive orthostatic tachycardia WITHOUT orthostatic hypotension 1. This is a critical distinction that makes droxidopa mechanistically inappropriate.
Limited and Disappointing Evidence in POTS
The available research on droxidopa in POTS is sparse and discouraging:
A 2017 retrospective study of 37 POTS patients found that while some symptoms improved (dizziness decreased from 91.9% to 75.7%), only 27% reported improved quality of life, and 40.5% stopped treatment due to side effects or ineffectiveness 3. There was no significant change in blood pressure.
A 2023 systematic review acknowledged droxidopa has been studied but noted most POTS drug studies are severely underpowered with sample sizes of only 10-50 subjects 4.
Recommended Treatment Algorithm for POTS
First-Line: Non-Pharmacological (ALL patients)
- Fluid intake: ≥3 L daily 1
- Salt intake: 10 g NaCl daily 1
- Exercise training: Semi-recumbent aerobic exercise (rowing, recumbent cycling, swimming) at least 4 days/week for ≥30 minutes 1
- Compression garments: Waist-high stockings (20-30 mm Hg) 1
- Head-up tilt sleeping: >10° elevation 1
Second-Line: Pharmacological (if disabling symptoms persist)
For patients with low blood pressure phenotype:
- Midodrine 2.5-15 mg every 4 hours up to 3 times daily (Strong Recommendation, Moderate-Quality Evidence) 1
For patients with high heart rate and palpitations:
- Low-dose propranolol 10-20 mg four times daily (Strong Recommendation, Moderate-Quality Evidence) 1
- Avoid long-acting formulations—they worsen fatigue and exercise tolerance 1
Additional options:
- Pyridostigmine: Especially useful when combined with β-blockers; helpful in patients with constipation but avoid in those with diarrhea or bladder dysfunction 1
- Ivabradine 2.5-7.5 mg twice daily: For heart rate control (Weak Recommendation, Low-Quality Evidence) 1
- Fludrocortisone: For volume expansion when oral salt intake inadequate; avoid in migraine patients; monitor potassium 1
Critical Pitfalls to Avoid
Do not confuse POTS with nOH: POTS patients do NOT have orthostatic hypotension by definition. Using droxidopa, which is designed to raise blood pressure in nOH, is mechanistically inappropriate 1, 2.
Supine hypertension risk: Droxidopa carries a black box warning for supine hypertension 2. POTS patients, particularly those with hyperadrenergic phenotype, may already have elevated blood pressure and would be at increased risk.
No long-term evidence: The FDA label notes droxidopa's effectiveness beyond 2 weeks has not been established 2, making it unsuitable for chronic POTS management.
Cost and access barriers: The 2017 study noted many patients couldn't obtain droxidopa due to insurance and cost concerns 3.
Bottom Line
Use guideline-recommended therapies: Start with midodrine for hypotensive patients or low-dose propranolol for tachycardic patients, both of which have moderate-quality evidence supporting their use in POTS 1. Droxidopa should be reserved for its FDA-approved indication of neurogenic orthostatic hypotension, not POTS.